CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy

CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy

Objective: Nonproliferative diabetic retinopathy (NPDR) is a progressive disease that can lead to blindness. Current therapies for NPDR are invasive and not extensively used or accessible until the disease progresses, pointing to the need for an early noninvasive treatment. The objective of CANBERRA...

Full description

Saved in:
Bibliographic Details
Main Authors: Beatriz G. Armendariz, PhD, Ulrich F.O. Luhman, PhD, Brian Berger, MD, Jules Hernandez-Sanchez, PhD, Katrijn Bogman, PhD, Nikolaos Mitrousis, PhD, Martina Wollenhaupt, MD, David Kent, MD, Andreas Wenzel, PhD, Sascha Fauser, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Ophthalmology Science
Subjects:
Cannabinoid receptor 2 agonist
Diabetic retinopathy
Oral treatment
Ph2
Online Access:http://www.sciencedirect.com/science/article/pii/S2666914524001866
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666914524001866

Similar Items